TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study presented at the 2026 EADV Congress found that nail detachment and discoloration were reported more often by people taking GLP-1 drugs than by nonusers. The cross-sectional findings show an association, not proof that the medications caused the changes; researchers say weight loss and other factors may also contribute.
A multinational study presented at the European Academy of Dermatology and Venereology Congress 2026 found that people taking GLP-1 medications reported nail detachment and discoloration more often than people who had never used the drugs. The comparison does not show that the medications caused the problems, and researchers say the findings should prompt awareness and discussion with clinicians—not unsupervised treatment changes.
Researchers compared 575 GLP-1 medication users with 1,329 nonusers who had type 2 diabetes and/or obesity. Participants were recruited in France, the United States, Brazil and Mexico. Overall, 66% of users reported at least one nail disorder, compared with 53% of the comparison group.
Nail discoloration was reported by 46% of users and 17% of nonusers. Nail detachment—the separation of a nail from the skin beneath it—was reported by 39% of users, compared with 9% of people who had never taken the medications. These are reported experiences in the study population, not estimates that every patient taking a GLP-1 drug will develop a nail problem.
The researchers said the association persisted after they accounted for some other factors. Among participants who had lost weight, users still reported more nail problems than nonusers. Adjustments for existing skin conditions and nutritional deficiencies narrowed some group differences, but nail detachment and discoloration remained about two to three times more common among users, according to the report.
Nail Changes May Deserve Clinical Attention
The findings matter because GLP-1 medicines are used by people with type 2 diabetes and obesity, and nail changes have not been well studied in relation to these treatments. Until this controlled comparison, information about possible nail effects had largely come from individual reports. The study gives clinicians and patients a larger set of observations to discuss, while leaving the cause unsettled.
The results do not establish that a drug directly affects nail growth or attachment. Changes in weight, nutrition, underlying health conditions and other factors could play a role, and the researchers found that some participants had nail problems before treatment. The study is a reason to report new or concerning symptoms to a health professional, not a basis for concluding that all such changes are medication side effects.
The report also describes a companion analysis of the same participants’ hair and scalp symptoms. Unusual hair loss was reported by 50% of users and 34% of nonusers; scalp redness was also more frequent among users. Those observations may support further research into skin and hair symptoms during treatment, but they do not prove a shared biological cause.
From Anecdotal Reports to Comparison
GLP-1 receptor agonists—including medicines marketed as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza and Trulicity—act on hormone signaling involved in blood sugar and appetite regulation. They are used for type 2 diabetes and, for some products and patients, weight management. Their growing use has led researchers to examine possible effects beyond their established treatment purposes.
Before this study, reports of nail changes during GLP-1 treatment were described as largely anecdotal. The researchers presented the work as the first controlled study of a possible relationship between these medicines and nail health. Its comparison group included people with diabetes and/or obesity who had not taken GLP-1 drugs, offering a reference point while not eliminating differences between the groups.
Study author Dr. Charles Taïeb said the results show an association but cautioned against assuming every event during treatment is caused by the medicine. The researchers also noted that roughly half of the medication users said they had experienced nail problems before starting treatment, a finding that complicates attempts to identify when or why the symptoms began.
“Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.”
— Dr. Charles Taïeb, study author
Cause and Timing Remain Unsettled
The study was cross-sectional: it compared reported experiences rather than following participants over time to establish whether symptoms began after treatment, changed with continued use or resolved after treatment ended. That design cannot determine whether GLP-1 medicines caused the nail problems.
Other questions remain, including whether particular drugs, doses or durations of use are associated with different risks. The report does not establish a mechanism, and the researchers said weight loss alone did not fully explain the pattern. Existing nail symptoms, skin conditions and nutritional deficiencies may also affect the comparisons. The findings rely on participant reports, and the supplied study account does not provide detailed results for each individual medication.
Discuss Symptoms With a Clinician
People taking a GLP-1 medication who notice nail separation, discoloration, hair shedding or scalp irritation should raise the change with their clinician, particularly if it is persistent or worsening. The researchers said patients should not stop an effective treatment on their own initiative. A clinician can review when symptoms began and consider other possible explanations, including health conditions or nutritional factors.
Further research will need to follow patients over time and compare symptoms before and after treatment begins. Studies that account for specific medicines, treatment duration, weight change and pre-existing conditions could help clarify whether the association reflects a drug effect, related changes in health, or a combination. For now, the congress findings are an early signal for discussion and investigation, not a confirmed medication warning.
Key Questions
Did the study prove GLP-1 drugs cause nail detachment?
No. It found an association between medication use and reported nail problems, but its cross-sectional design cannot prove that the drugs caused them.
How common was nail detachment in the study?
39% of GLP-1 users reported nail detachment, compared with 9% of people in the study who had never used the medications. Those figures describe the participants surveyed, not all people taking these drugs.
Could weight loss explain the nail findings?
The researchers found that weight loss did not fully account for the differences: users who had lost weight still reported more nail problems than nonusers. Other factors may contribute, and the study does not identify a definitive cause.
Should someone stop taking a GLP-1 medicine if their nails change?
The researchers said not to stop an effective treatment without speaking to a doctor. People who notice nail or scalp changes should discuss them with their clinician.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
